BlackRock Group’s Opus Genetics IRD Stock Holding History

BlackRock Group’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-657	Closed	-$340K	–	2870
2014 Q1	$340K	Buy	+657	New	+$355K	﹤0.01%	2341

Other funds holding IRD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

NFC

Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

CCM

Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return

BlackRock Group's IRD Position: Q2 2014 in Review

BlackRock Group sold out of Opus Genetics (IRD) in Q2 2014, closing a stake of 657 shares — an estimated $340K sold.

BlackRock Group first reported a position in IRD in Q1 2014 and held it in 1 quarter. The position peaked at $340K in Q1 2014. 35 funds tracked by Wall St. Rank hold IRD as of Q2 2014.

BlackRock Group reported no remaining Opus Genetics position as of Q2 2014 after selling out during the quarter.
BlackRock Group sold 657 Opus Genetics shares in Q2 2014, an estimated $340K.
BlackRock Group first reported a position in Opus Genetics in Q1 2014 and held it in 1 quarter.
BlackRock Group's Opus Genetics position peaked at $340K in Q1 2014.
35 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2014.

Based on BlackRock Group's 13F filing for Q2 2014, filed 6 Aug 2014.